A panel of multiplex immunofluorescence for different prognostic markers (i.e., CD3 as pan T lymphocytes, CD4 for T helper cells, CD8 for cytotoxic T lymphocytes, FoxP3 for Treg lymphocytes, and PD-L1) combined with DAPI to evaluate which analytical approach was best suited to combine morphologic and immunohistochemical data into a cancer score to identify the area of cancer that best matched an independent pathologist assignment [92]. The gene discussed is CD8A; the disease is cancer.